TrialNature communications2026

Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.

Yuchen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.